{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
M016
(2023)
Source URL:
First approved in 2023
Source:
M016
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 358H
(2013)
Source URL:
First approved in 2013
Source:
21 CFR 358H
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 346
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT00790140: Phase 4 Interventional Unknown status Esophageal Cancer
(2005)
Source URL:
First approved in 1984
Source:
NeuroBion by BENARD INDUSTRIES INC
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT01145560: Phase 2 Interventional Completed Severe Sepsis
(2010)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01483287: Early Phase 1 Interventional Completed Irritable Bowel Syndrome
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
